Management and Outcomes of Idiopathic Central Precocious Puberty in Girls

(Pages 16-22)
Rossella Gaudino1, Valeria Calcaterra2, Giovanni Farello3, Manuela Gasparri4, Claudio Maria Monti5, Elena Bozzola6, Alberto Villani6 and Mauro Bozzola7

1Department of Surgery, Dentistry, Pediatrics and Gynecology, Section of Pediatrics, University of Verona, Italy; 2Department of Internal Medicine and Therapeutics, Pediatrics and Adolescent Care Unit, University of Pavia and Children’s Hospital “Vittore Buzzi”, Milano, Italy; 3Department of Life, Health and Environmental Sciences, Pediatric Unit, University of L’Aquila, Italy; 4Department of Pediatrics, San Paolo Hospital, Milan, Italy; 5Adolfo Ferrata Medical Library, University of Pavia, Italy; 6Department of Pediatrics, Unit of Pediatric and Infectious Diseases, Bambino Gesù Children Hospital IRCCS, Rome, Italy; 7University of Pavia and Onlus Il bambino e il suo pediatra, via XX Settembre 28, 28066 Galliate (Novara), Italy

DOI: https://doi.org/10.12974/2311-8687.2020.08.3

Download

Abstract: The sequelae of early development are not merely transient but are predictive of difficulties and challenges that persist into adulthood. In fact, the diagnosis and appropriate treatment of early puberty is essential in order to avoid permanent auxological and emotional consequences. GnRH analogues are the treatment of choice for central precocious puberty (CPP), whose main objective is to recover the height potential that is compromised by the premature fusion of growth cartilages. Several active principles and formulations are available. Depot formulations are generally preferred because of better patient compliance; GnRH-a is generally safe and well tolerated. Drug choice depends on the physician’s experience, patient needs, and government regulations of drug prescription.
The aim of this review is to examine the treatment of Idiopathic Central CPP taking in account clinical practice and international literature.

Keywords: Puberty, Precocious puberty, Pubertal progression, Early puberty, Gonadotropin-releasing hormone (GnRH), GnRH agonists, GnRHa histrelin.